Compositions and methods for treating or preventing vasomotor symptoms

Abstract

The present disclosure is directed to compositions comprising as an active ingredient, a lower dose of 4-({(4-cyclopropylisoquinolin-3-yl)[4-(trifluoromethoxy)benzyl]amino}sulfonyl)benzoic acid or a pharmaceutically acceptable salt thereof for treating or preventing vasomotor symptoms in a subject, and methods which comprises administering the said compound or the pharmaceutically acceptable salt thereof at a lower dose, respectively.

1 - 28 . (canceled) 
     
     
         29 . A method for treating or preventing vasomotor symptoms in a subject in need thereof, the method comprising:
 administering to the subject 4-({(4-cyclopropylisoquinolin-3-yl)[4-(trifluoromethoxy)benzyl]amino}sulfonyl)benzoic acid or a pharmaceutically acceptable salt thereof at a daily dose of 10 mg or less.   
     
     
         30 . A method for treating or preventing vasomotor symptoms in a subject in need thereof, the method comprising:
 administering to the subject 4-({(4-cyclopropylisoquinolin-3-yl)[4-(trifluoromethoxy)benzyl]amino}sulfonyl)benzoic acid or a pharmaceutically acceptable salt thereof at a daily dose of 10 mg or less,   wherein the 4-({(4-cyclopropylisoquinolin-3-yl)[4-(trifluoromethoxy)benzyl]amino}sulfonyl)benzoic acid or pharmaceutically acceptable salt thereof is administered in a composition, and the composition comprises a pharmaceutically acceptable carrier.   
     
     
         31 . The method according to  claim 30 , wherein the daily dose ranges from 1 mg to 10 mg. 
     
     
         32 . The method according to  claim 30 , wherein the daily dose is chosen from 1 mg, 5 mg, and 10 mg. 
     
     
         33 . The method according to  claim 30 , wherein the subject is a human subject. 
     
     
         34 . The method according to  claim 33 , wherein the human subject is a menopausal woman, a perimenopausal woman or a postmenopausal woman. 
     
     
         35 . The method according to  claim 33 , wherein the human subject is a cancer patient. 
     
     
         36 . The method according to  claim 33 , wherein the human subject is undergoing or has undergone a treatment for cancer. 
     
     
         37 . The method according to  claim 36 , wherein the treatment for cancer is gonadal ablative therapy or gonadal hormonal suppressive therapies. 
     
     
         38 . The method according to  claim 33 , wherein the human subject has undergone a surgery. 
     
     
         39 . The method according to  claim 30 , wherein the vasomotor symptoms are hot flashes or night sweats. 
     
     
         40 . The method according to  claim 30 , wherein the 4-({(4-cyclopropylisoquinolin-3-yl)[4-(trifluoromethoxy)benzyl]amino}sulfonyl)benzoic acid or pharmaceutically acceptable salt thereof is administered with onset of the vasomotor symptom. 
     
     
         41 . The method according to  claim 30 , wherein the 4-({(4-cyclopropylisoquinolin-3-yl)[4-(trifluoromethoxy)benzyl]amino}sulfonyl)benzoic acid or pharmaceutically acceptable salt thereof is administered daily. 
     
     
         42 . The method according to  claim 41 , wherein the 4-({(4-cyclopropylisoquinolin-3-yl)[4-(trifluoromethoxy)benzyl]amino}sulfonyl)benzoic acid or pharmaceutically acceptable salt thereof is administered once daily or twice daily. 
     
     
         43 . The method according to  claim 29 , wherein the daily dose of the 4-({(4-cyclopropylisoquinolin-3-yl)[4-(trifluoromethoxy)benzyl]amino}sulfonyl)benzoic acid or pharmaceutically acceptable salt thereof is administered with an additional active agent. 
     
     
         44 . A pharmaceutical composition comprising an amount of 4-({(4-cyclopropylisoquinolin-3-yl)[4-(trifluoromethoxy)benzyl]amino}sulfonyl)benzoic acid or a pharmaceutically acceptable salt thereof of 10 mg or less and a pharmaceutically acceptable carrier, wherein the composition treats or prevents vasomotor symptoms in a subject in need thereof.